Meeting
2018 ASCO Annual Meeting
Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy.
Authors
Magda Zajac
AstraZeneca, Cambridge, United Kingdom
Magda Zajac , Jiabu Ye , Pralay Mukhopadhyay , Xiaoping Jin , Yong Ben , Joyce Antal , Ashok Kumar Gupta , Marlon Rebelatto , J. Andrew Williams , Jill Walker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT01693562
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4530)
DOI
10.1200/JCO.2018.36.15_suppl.4530
Abstract #
4530
Poster Bd #
356
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Regulatory approvals for genitourinary (GU) cancer by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) over 20 years (2003-2023).
First Author: Sanjay Khanna
Poster
2023 ASCO Annual Meeting
Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.
First Author: Nourhan El Ahmar
Poster
2022 ASCO Annual Meeting
Prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma (mUC) treated with durvalumab (D) with or without tremelimumab (T) in the DANUBE study.
First Author: Carlos Stecca
Poster
2022 ASCO Annual Meeting
FoRT 05-BEAT: A phase II randomized trial comparing atezolizumab versus atezolizumab + bevacizumab as first-line treatment in patients with PD-L1 high advanced/metastatic NSCLC.
First Author: Rita Migliorino